Shopping Cart
Remove All
Your shopping cart is currently empty
Sugemalimab
Catalog No. T76714 Copy Product Info
Purity: 95%
🥰Excellent
Sugemalimab (CS1001) is a fully humanized, full-length monoclonal antibody targeting PD-L1. It cross-links PD-L1-positive tumor cells with macrophages, inducing antibody-dependent cellular cytotoxicity. Sugemalimab is being studied for EGFR mutation-negative and ALK-negative metastatic non-small cell lung cancer (NSCLC), advanced solid tumors, and lymphoma.
Sugemalimab
Copy Product Info🥰Excellent
Catalog No. T76714
Sugemalimab (CS1001) is a fully humanized, full-length monoclonal antibody targeting PD-L1. It cross-links PD-L1-positive tumor cells with macrophages, inducing antibody-dependent cellular cytotoxicity. Sugemalimab is being studied for EGFR mutation-negative and ALK-negative metastatic non-small cell lung cancer (NSCLC), advanced solid tumors, and lymphoma.
Sugemalimab
Cas No. 2256084-03-2
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $539 | - | In Stock | |
| 5 mg | $1,380 | - | In Stock | |
| 10 mg | $2,120 | - | In Stock | |
| 25 mg | $3,900 | - | In Stock |
In stock · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:95%
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Sugemalimab (CS1001) is a fully humanized, full-length monoclonal antibody targeting PD-L1. It cross-links PD-L1-positive tumor cells with macrophages, inducing antibody-dependent cellular cytotoxicity. Sugemalimab is being studied for EGFR mutation-negative and ALK-negative metastatic non-small cell lung cancer (NSCLC), advanced solid tumors, and lymphoma. |
| In vitro | Sugemalimab (CS1001) specifically binds PD-L1, competitively blocking human PD-L1 from interacting with PD-1 and CD80, thereby inducing CD4+ T lymphocyte proliferation and enhancing IFN-γ and IL-2 production. Sugemalimab lacks antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) [2]. |
| In vivo | In a human PD-1 knock-in mouse model, Sugemalimab (CS1001) significantly inhibited tumor growth in subcutaneously implanted MC38-hPD-L1 mouse colon carcinomas, increased the cytotoxic T cell/regulatory T cell ratio, and markedly upregulated M1 macrophages while downregulating myeloid-derived suppressor cells (MDSCs) [2]. |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | PD-L1 |
| Cas No. | 2256084-03-2 |
| Isotype | Human IgG4 lambda |
| Storage | store at low temperature | store at -80°C | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Sugemalimab | purchase Sugemalimab | Sugemalimab cost | order Sugemalimab | Sugemalimab in vivo | Sugemalimab in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.